Solusomes (novel soluplus enriched nano-vesicular carriers) for improving the oral bioavailability of Candesartan cilexetil.

Candesartan cilexetil (CAN) is administered for treating hypertension and heart failure. CAN suffers poor oral bioavailability, owing to limited aqueous solubility, and first-pass metabolism. Solusomes (novel Soluplus enriched nano-vesicular carriers) combine the merits of Soluplus, and the traditional liposomes.